Nifty
:
16992.55
Sensex
:
57720.37
47.50 (0.28%)
193.27 (0.34%)
Nifty
Sensex
:
:
16992.55
57720.37
47.50 (0.28%)
193.27 (0.34%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
46/99

BSE: 500257 | NSE: LUPIN

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 29,107.43
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,853.46
  • 0.63%
  • 2.42

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.10%
  • 0.72%
  • 8.06%
  • FII
  • DII
  • Others
  • 13.98%
  • 27.86%
  • 2.28%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.46
  • 0.75
  • -0.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -20.99
  • -41.52
  • -38.64

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 77.41

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.19
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.05
  • 2.94
  • 3.14

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.85
  • 14.81
  • 16.03

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
4,322.22
4,160.93
3.88%
4,145.52
4,091.33
1.32%
3,743.84
4,270.19
-12.33%
3,883.03
3,783.10
2.64%
Expenses
3,789.55
3,791.10
-0.04%
3,692.53
5,415.18
-31.81%
3,579.90
3,342.62
7.10%
3,656.58
3,075.55
18.89%
EBITDA
532.67
369.83
44.03%
452.99
-1,323.85
-
163.94
927.57
-82.33%
226.45
707.55
-68.00%
EBIDTM
12.32%
8.89%
10.93%
-32.36%
4.38%
21.72%
5.83%
18.70%
Other Income
17.96
34.06
-47.27%
14.94
72.81
-79.48%
73.94
64.99
13.77%
57.05
58.22
-2.01%
Interest
84.09
33.40
151.77%
54.88
34.43
59.40%
42.78
33.47
27.82%
41.47
31.84
30.24%
Depreciation
220.40
203.43
8.34%
203.47
919.33
-77.87%
192.83
208.76
-7.63%
327.19
215.72
51.67%
PBT
246.14
167.06
47.34%
209.58
-2,204.80
-
2.27
750.33
-99.70%
-85.16
518.21
-
Tax
88.49
-382.00
-
75.11
-109.91
-
89.09
202.33
-55.97%
426.73
54.01
690.09%
PAT
157.65
549.06
-71.29%
134.47
-2,094.89
-
-86.82
548.00
-
-511.89
464.20
-
PATM
3.65%
13.20%
3.24%
-51.20%
-2.32%
12.83%
-13.18%
12.27%
EPS
3.37
12.01
-71.94%
2.85
-46.21
-
-1.96
11.95
-
-11.40
10.15
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
16,094.61
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
9,641.30
Net Sales Growth
-1.29%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
17.06%
 
Cost Of Goods Sold
6,661.94
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
3,221.50
Gross Profit
9,432.67
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
GP Margin
58.61%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
66.59%
Total Expenditure
14,718.56
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
7,371.41
Power & Fuel Cost
-
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
% Of Sales
-
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
3.32%
Employee Cost
-
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
% Of Sales
-
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
13.14%
Manufacturing Exp.
-
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
% Of Sales
-
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
10.13%
General & Admin Exp.
-
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
692.06
% Of Sales
-
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
7.18%
Selling & Distn. Exp.
-
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
709.62
% Of Sales
-
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
7.36%
Miscellaneous Exp.
-
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
283.96
709.62
% Of Sales
-
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
1.92%
EBITDA
1,376.05
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
EBITDA Margin
8.55%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
23.54%
Other Income
163.89
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
Interest
223.22
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
Depreciation
943.89
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
PBT
372.83
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
Tax
679.42
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
Tax Rate
182.23%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
PAT
-306.59
-1,528.40
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
PAT before Minority Interest
-324.02
-1,509.72
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
Minority Interest
-17.43
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
PAT Margin
-1.90%
-9.32%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
13.63%
PAT Growth
0.00%
-
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
 
EPS
-6.74
-33.61
26.72
-6.02
13.45
5.45
56.05
49.60
52.84
40.38
28.90

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
Share Capital
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
Total Reserves
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
Non-Current Liabilities
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
Secured Loans
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
Unsecured Loans
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
Long Term Provisions
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
Current Liabilities
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
Trade Payables
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
Other Current Liabilities
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
Short Term Borrowings
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
Short Term Provisions
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
Total Liabilities
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
Net Block
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
Gross Block
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
Accumulated Depreciation
7,768.47
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
Non Current Assets
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
Capital Work in Progress
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
Non Current Investment
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
Long Term Loans & Adv.
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
Other Non Current Assets
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
Current Assets
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
Current Investments
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
Inventories
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
Sundry Debtors
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
Cash & Bank
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
Other Current Assets
1,644.48
556.89
537.33
777.47
1,711.95
1,191.01
1,241.22
534.98
532.99
572.33
Short Term Loans & Adv.
1,112.46
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
Net Current Assets
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
Total Assets
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
PBT
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
Adjustment
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
Changes in Working Capital
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
Cash after chg. in Working capital
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
Net Fixed Assets
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
Net Investments
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
Others
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
Cash from Financing Activity
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
Net Cash Inflow / Outflow
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
Opening Cash & Equivalents
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
Closing Cash & Equivalent
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
ROA
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
ROE
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
ROCE
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
Fixed Asset Turnover
1.97
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
2.19
Receivable days
52.62
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
74.61
Inventory Days
52.54
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
69.24
Payable days
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
63.78
63.76
Cash Conversion Cycle
-27.39
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
76.37
80.10
Total Debt/Equity
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
Interest Cover
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Lupin gets USFDA’s tentative approval for Valbenazine Capsules
    27th Mar 2023, 10:59 AM

    Valbenazine Capsules had estimated annual sales of $1,235 million in the U.S.

    Read More
  • UK MHRA concludes inspection at Lupin’s Pithampur facilities in India
    27th Mar 2023, 09:28 AM

    The inspection was conducted from March 20, 2023 to March 24, 2023

    Read More
  • Lupin gets USFDA’s tentative approval for Obeticholic Acid Tablets
    23rd Mar 2023, 16:15 PM

    Obeticholic Acid Tablets had estimated annual sales of $255 million in the U.S.

    Read More
  • Lupin receives USFDA’s approval for Brexpiprazole Tablets
    21st Mar 2023, 15:36 PM

    This product would be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin’s alliance partner gets USFDA’s final approval for Rocuronium Bromide Injection
    20th Mar 2023, 18:06 PM

    Rocuronium Bromide Injection had an annual sale of around $53 million in the U.S.

    Read More
  • Lupin’s alliance partner gets USFDA’s final approval for Thiamine Hydrochloride Injection
    20th Mar 2023, 17:13 PM

    Thiamine Hydrochloride Injection USP had an annual sale of around $36 million in the U.S.

    Read More
  • Lupin’s arm unveils results of India’s First Digital Therapeutics Study with ACS Patients
    17th Mar 2023, 13:00 PM

    The study findings were presented at the India Live 2023 symposium in Chennai

    Read More
  • USFDA completes inspection at Lupin’s Bioresearch Centre in Pune
    13th Mar 2023, 17:40 PM

    The inspection closed without any observation

    Read More
  • USFDA completes GMP Inspection at Lupin’s API manufacturing facility in Visakhapatnam
    11th Mar 2023, 12:56 PM

    The inspection was conducted from March 6, 2023 to March 10, 2023 and concluded with no observations

    Read More
  • Lupin’s arm launches new regional reference laboratory in Hyderabad
    1st Mar 2023, 15:37 PM

    Lupin Diagnostics is committed to making preventive quality healthcare accessible and affordable to all

    Read More
  • Lupin launches Lurasidone Hydrochloride Tablets in United States
    21st Feb 2023, 14:36 PM

    Lurasidone Hydrochloride Tablets had estimated annual sales of $4.2 billion in the United States

    Read More
  • Lupin gets EIR for new injectable facility in Nagpur
    17th Feb 2023, 09:58 AM

    The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022

    Read More
  • Lupin reports 71% fall in Q3 consolidated net profit
    10th Feb 2023, 11:08 AM

    Total consolidated income of the company increased by 3.46% to Rs 4,340.18 crore for Q3FY23

    Read More
  • Lupin - Quarterly Results
    9th Feb 2023, 21:56 PM

    Read More
  • Lupin receives USFDA’s approval for Glycopyrrolate Injection
    9th Feb 2023, 10:59 AM

    The product marks the first approval from Lupin’s new injectable facility in Nagpur

    Read More
  • Lupin gets USFDA’s tentative approval for DETAF Tablets
    31st Jan 2023, 12:23 PM

    This product would be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin’s arm launches digital therapeutics solution 'LYFE'
    24th Jan 2023, 15:41 PM

    LYFE is India’s only evidence-based holistic heart care programme that significantly reduces the risk of a heart attack

    Read More
  • Lupin’s arm recalling 16,056 bottles of Rifampin Capsules in US market
    21st Jan 2023, 15:06 PM

    The affected lot has been produced at Lupin's Aurangabad plant

    Read More
  • Lupin launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients
    18th Jan 2023, 14:58 PM

    Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg

    Read More
  • Lupin gets USFDA’s tentative approval for Dolutegravir and Rilpivirine Tablets
    16th Jan 2023, 14:41 PM

    Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, had estimated annual sales of USD 666 million in the U.S.

    Read More
  • USFDA completes inspection at Lupin’s Somerset manufacturing facility
    16th Jan 2023, 10:11 AM

    The inspection closed with issuance of a Form-483 with two observations

    Read More
  • Lupin receives USFDA’s approval for Prasugrel Tablets
    10th Jan 2023, 15:08 PM

    The product will be manufactured at Lupin’s facility in Goa

    Read More
  • Lupin gets reimbursement approval of NaMuscla in Spain
    10th Jan 2023, 09:58 AM

    NaMuscla, which has been designated orphan drug status, received EU marketing authorization in December 2018

    Read More
  • Lupin gets USFDA’s nod for Fesoterodine Fumarate Extended-Release Tablets
    6th Jan 2023, 17:36 PM

    The product will be manufactured at Lupin’s facility in Goa, India

    Read More
  • Lupin launches novel fixed-dose triple drug for managing inadequately controlled asthma amongst patients
    5th Jan 2023, 11:29 AM

    The company has launched this important product under the brand name DIFIZMA in India

    Read More
  • Lupin’s arm voluntarily recalling four lots of Quinapril Tablets
    22nd Dec 2022, 16:57 PM

    To date, Lupin has received no reports of illness that appear to relate to this issue

    Read More
  • Lupin launches Regional Reference Laboratory in Indore
    21st Dec 2022, 15:46 PM

    Lupin Diagnostics currently operates 325+ LupiMitra and 23 laboratories in India

    Read More
  • Lupin receives USFDA’s approval for Brivaracetam Tablets
    21st Dec 2022, 12:58 PM

    The product will be manufactured at Lupin’s facility in Nagpur, India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.